SAGE - Sage Therapeutics, Inc.
| Previous Close | 107.55 |
| Open | 109.44 |
| Bid | 109.90 x 1000 |
| Ask | 110.43 x 1100 |
| Day's Range | 107.48 - 111.78 |
| 52 Week Range | 100.16 - 195.97 |
| Volume | 182,246 |
| Avg. Volume | 408,050 |
| Market Cap | 5.164B |
| Beta (3Y Monthly) | 3.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.39 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 203.20 |
- CNBC Videos•last month
FDA set to review new drugs aimed at fighting depression
CNBC's Meg Tirrell reports on the FDA set to review two new depression drugs and what it could mean for the pharma companies behind the drugs.
- Insider Monkey•yesterday
Hedge Funds Are Selling SAGE Therapeutics Inc (SAGE)
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
- Business Wire•6 days ago
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 3, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 156,100 shares of its common stock to 93 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- ACCESSWIRE•11 days ago
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 30, 2018 / U.S. markets closed lower on Thursday as investors await details from this weekend's trade meeting between President Trump and Chinese President Xi Jinping. ...
- GlobeNewswire•12 days ago
New Research: Key Drivers of Growth for Upland Software, VICI Properties, Sage Therapeutics, Jack Henry & Associates, T2 Biosystems, and Tata Motors — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•15 days ago
Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 26, 2018 / U.S. equities lost footing on Friday amidst drop in oil prices and selloff in FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet) stocks. ...
- Business Wire•20 days ago
Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018 at 09:30 A.M.
- Business Wire•21 days ago
Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO™ (brexanolone) Injection
Sage Therapeutics, Inc. (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its Priority Review of the New Drug Application (NDA) for ZULRESSO™ (brexanolone) injection for the treatment of postpartum depression (PPD). The previously disclosed December 19, 2018 PDUFA goal date has been extended by a period of three months to March 19, 2019.
- Thomson Reuters StreetEvents•24 days ago
Edited Transcript of SAGE earnings conference call or presentation 6-Nov-18 1:00pm GMT
Q3 2018 SAGE Therapeutics Inc Earnings Call
- ACCESSWIRE•25 days ago
Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The ...
- CNBC•29 days ago
Stocks making the biggest moves after hours: PG&E, Eventbrite and more
State regulators are investigating whether the utilities company's facilities were involved in the beginning of the California wildfires that have killed 31 people. The drop came after Leerink, an investment bank focused on health care, described the company as its least favorite in the biopharmaceutical space, giving the stock a price target of $80 -- well below Monday's closing price of $121.44. Leerink said Sage's drug for postpartum depression, Zulresso, is a niche product that will have low peak sales and a slow ramp after approval.
- Business Wire•last month
Sage Therapeutics to Present at Stifel 2018 Healthcare Conference
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 09:30 A.M.
- Business Wire•last month
Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
FDA Advisory Committee Meeting outcome supports approval of ZULRESSO™ injection as the first medicine specifically indicated for the treatment of postpartum depressio
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval for postpartum depression. AcelRx Pharmaceuticals, Inc. shares closed up 15.66% on about 20 million shares traded on Friday.
- Business Wire•last month
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,400 shares of its common stock to 12 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- Reuters•last month
FDA panel recommends Sage's postpartum depression treatment
An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks. The panel voted 17-1 in favor of the injectable treatment, Zulresso, which aims to treat major episodes of depression during pregnancy or within four weeks of delivery. "I believe that (Zulresso) may be a game changer in the treatment of postpartum depression.
- Business Wire•last month
Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) jointly voted (17 yes, 1 no) that data support the favorable benefit-risk profile of ZULRESSO™ (brexanolone) injection for the treatment of postpartum depression (PPD) when administered by qualified staff in a facility that has been certified under a Risk Evaluation and Mitigation Strategies (REMS) program. “We are pleased the FDA Advisory Committee agreed that the benefit/risk profile of ZULRESSO supports this novel approach to treating PPD, reflecting the need for an innovative treatment option that may rapidly alleviate suffering for women with PPD and their families,” said Jeff Jonas, M.D., chief executive officer of Sage.
- American City Business Journals•last month
FDA committee recommends Sage's postpartum depression drug
The first-ever drug to treat postpartum depression, developed by Cambridge-based Sage Therapeutics Inc., appears set for likely approval by the FDA after favorable votes on three key questions by members of an advisory committee Friday. The 18 members of the FDA's Psychopharmacologic Drugs Advisory Committee voted unanimously to say the trial data on the drug by Sage (Nasdaq: SAGE), which would be sold as Zulresso, provided "substantial evidence ... to support a claim of effectiveness... for the treatment of postpartum depression." In the second vote, 16 members said the company "adequately characterized the safety profile" of the drug, with two members abstaining. The third vote, 17 members voted yes and one voted no on the question, "do the benefits outweigh the risks of brexanolone for the treatment of postpartum depression?" The FDA has until Dec. 19 to decide whether or not to approve the drug for sale in the U.S. Although the regulator doesn't have to follow the recommendations of its advisory committees, it usually does.
- MarketWatch•last month
Sage Therapeutics shares halted ahead of regulatory meeting on post-partum treatment
Sage Therapeutics Inc. said Friday its stock has been halted premarket ahead of a joint meeting of the U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee to discuss its Zulresso treatment for postpartum depression. The meeting is scheduled for 8.00 a.m. Eastern to 5.00 p.m. Shares have fallen 16.5% in 2018, while the S&P 500 has gained 2.5%.
- Business Wire•last month
Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO™ (brexanolone) Injection for the Treatment of Postpartum Depression
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that NASDAQ has halted trading of the company’s common stock.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Exelixis and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During ...
- TheStreet.com•2 months ago
Sage Therapeutics Turned Down - Don't Rush to Be a Buyer
was mentioned in the fast paced "Lightning Round" on Jim Cramer's "Mad Money" program Thursday night. In this daily bar chart of SAGE, below, we can see that prices drifted sideways from February to the end of August but after that prices broke support and started a better defined downtrend. SAGE is also below the 200-day moving average line whose slope turned negative in late September.
- CNBC•2 months ago
Cramer's lightning round: 'Take the money and run' with takeover stock Mazor Robotics
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Mazor Robotics Ltd. MZOR-IL : " It's being bought , so it's kind of done. Take-Two Interactive Software TTWO : "OK, Take-Two Interactive got some incredible reviews for 'Red Dead Redemption [2].' The stock's up big.
Market Realist•2 months agoHow Wall Street Analysts View Alkermes after Q3 Earnings Release
On October 24, Alkermes (ALKS) stock closed at $40.03, which is 44% below its 52-week high of $71.22 on February 16. On October 23, the stock closed at $40.19, which is a ~3.42% rise from its prior day’s close of $38.86. Also on October 23, Alkermes hit its 52-week low of $37.01. In September, Alkermes announced that it has initiated an expansion of its ongoing Phase 1 trial.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Sage Therapeutics and Ionis Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / October 24, 2018 / U.S. stocks finished in the red on Tuesday, with the S&P 500 falling for the 5th consecutive session, as a drop in Asian markets continued to raise global ...
